---
title: "Donor-Derived Ehrlichia ewingii Infection After Pediatric Liver Transplant, US 2023"
id: "cdc-emerging-infectious-diseases-journal-1-transplant-associated-ehrlichia-ewingii-infection-in-pediatric-liver-recipient"
canonical_url: "https://medichelpline.com/clinical-feed/cdc-emerging-infectious-diseases-journal-1-transplant-associated-ehrlichia-ewingii-infection-in-pediatric-liver-recipient"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "CDC Emerging Infectious Diseases Journal"
source_url: "https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article"
published_at: "2026-11-19T05:00:00.000Z"
evidence_level: "Agency Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Donor-Derived Ehrlichia ewingii Infection After Pediatric Liver Transplant, US 2023
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/cdc-emerging-infectious-diseases-journal-1-transplant-associated-ehrlichia-ewingii-infection-in-pediatric-liver-recipient
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** CDC Emerging Infectious Diseases Journal
- **Source URL:** [Original Journal Publication](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article)
- **Published At:** 2026-11-19T05:00:00.000Z
- **Evidence Rating:** Agency Feed
## Executive GIST (TL;DR)
- A pediatric liver transplant recipient developed fever, nausea, dyspnea, and pancytopenia 18 days after surgery; clinicians observed clinical improvement within 24 hours of initiating **doxycycline**. - Peripheral blood smear showed morulae in granulocytes; real-time PCR and partial 16S rRNA sequencing confirmed **Ehrlichia ewingii** in recipient blood samples. - Donor lived in an area with reported human **E. ewingii** cases and had sought care 30 days before donation for a brief illness consistent with ehrlichiosis; donor serum had high-titer IgG reactive with **E. chaffeensis** (1:2,048) on retrospective testing. - CDC PCR did not detect **Ehrlichia** DNA in donor serum or in recipient pretransplant whole blood; liver biopsy specimens were negative by immunohistochemistry and PCR. - Multiple posttransplant whole-blood PCRs from the recipient remained positive through day 56, converted to negative on days 67–68, then reverted to intermittent low-level positive results; clinicians continued **doxycycline** for >273 days. - Kidney recipients from the same donor remained asymptomatic; their PCRs were negative, and serology was not performed. - Authors reported that clinical, geographic, and laboratory evidence strongly support a donor-derived **E. ewingii** infection, but limitations include negative donor PCRs and incomplete testing in other organ recipients. - The case emphasizes that rare tickborne pathogens can present as donor-derived infections in transplant recipients and that extended antimicrobial therapy may be required in immunosuppressed patients.
## Clinical Analysis & Structured Key Points
[Skip directly to page options](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article#share-nav) [Skip directly to A-Z link](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article#az-large) ![](https://wwwnc.cdc.gov/TemplatePackage/4.0/assets/imgs/uswds/us_flag_small.png) An official website of the United States government Here's how you know ![](https://wwwnc.cdc.gov/TemplatePackage/4.0/assets/imgs/uswds/icon-dot-gov.svg) **Official websites use .gov** A .gov website belongs to an official government organization in the United States. ![](https://wwwnc.cdc.gov/TemplatePackage/4.0/assets/imgs/uswds/icon-https.svg) **Secure .gov websites use HTTPS** A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. [CDC Home](https://wwwnc.cdc.gov/) [ ![Centers for Disease Control and Prevention](https://wwwnc.cdc.gov/TemplatePackage/5.0/img/logo/cdc-logo-tag-right.svg) ](https://www.cdc.gov/) Emerging Infectious Diseases ![](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article) [A-Z Index](https://www.cdc.gov/az/) × Submit [A-Z Index](https://www.cdc.gov/az/) × Submit [A-Z Index](https://www.cdc.gov/az/) Search Dropdown × Submit Emerging Infectious Diseases * [About the Journal](https://wwwnc.cdc.gov/eid/about) * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article) **About the Journal** * [General Information](https://wwwnc.cdc.gov/eid/about/general) * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article) **General Information** * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article) **About the Journal****General Information** * [Background and Goals](https://wwwnc.cdc.gov/eid/about/background) * [Editors](https://wwwnc.cdc.gov/eid/about/editors) * [Editorial Board](https://wwwnc.cdc.gov/eid/about/editorial-board) * [Staff](https://wwwnc.cdc.gov/eid/about/staff) * [ Home](https://wwwnc.cdc.gov/) * [Contact](https://wwwnc.cdc.gov/eid/contact) * [EID Journal Report 2025](https://wwwnc.cdc.gov/eid/pdfs/JournalReport_2025.pdf) * [ Home](https://wwwnc.cdc.gov/) * [Articles](https://wwwnc.cdc.gov/eid/) * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article) **Articles** * [December 2026](https://wwwnc.cdc.gov/eid/current) * [Wastewater Surveillance](https://wwwnc.cdc.gov/eid/articles/issue/32/13/table-of-contents) * [Early Release](https://wwwnc.cdc.gov/eid/early-release) * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article) **Early Release** * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article) **Articles****Early Release** * [Transplant-Associated Ehrlichia ewingii Infection in Pediatric Liver Recipient, United States, 2023](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article) * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article) **Transplant-Associated Ehrlichia ewingii Infection in Pediatric Liver Recipient, United States, 2023** * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article) **Early Release****Transplant-Associated Ehrlichia ewingii Infection in Pediatric Liver Recipient, United States, 2023** * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article) **Articles****Early Release****Transplant-Associated Ehrlichia ewingii Infection in Pediatric Liver Recipient, United States, 2023** * [Figure](https://wwwnc.cdc.gov/eid/article/32/14/26-1060-f1) * [Table](https://wwwnc.cdc.gov/eid/article/32/14/26-1060-t1) * [ Home](https://wwwnc.cdc.gov/) * [ Home](https://wwwnc.cdc.gov/) * [Past Issues](https://wwwnc.cdc.gov/eid/past-issues/volume-32) * [Medscape CME](https://wwwnc.cdc.gov/eid/articles/cme) * [ICEID](https://wwwnc.cdc.gov/eid/page/iceid) * [ Home](https://wwwnc.cdc.gov/) * [Search](https://wwwnc.cdc.gov/eid/Search) * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article) **Search** * [Advanced Article Search](https://wwwnc.cdc.gov/eid/AdvancedSearch) * [Articles by Country Search](https://wwwnc.cdc.gov/eid/ArticleMap) * [Spotlight Topics](https://wwwnc.cdc.gov/eid/spotlight) * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article) **Spotlight Topics** * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article) **Search****Spotlight Topics** * [Antimicrobial Resistance Spotlight](https://wwwnc.cdc.gov/eid/spotlight/antimicrobial-resistance) * [Coronavirus Spotlight](https://wwwnc.cdc.gov/eid/spotlight/coronavirus) * [Ebola Spotlight](https://wwwnc.cdc.gov/eid/spotlight/ebola) * [Etymologia](https://wwwnc.cdc.gov/eid/articles/etymologia) * [Foodborne Diseases and Outbreaks Spotlight](https://wwwnc.cdc.gov/eid/spotlight/foodborne-diseases) * [Fungal Diseases](https://wwwnc.cdc.gov/eid/spotlight/fungal) * [Hantavirus Spotlight](https://wwwnc.cdc.gov/eid/spotlight/hantavirus) * [HIV/AIDS Spotlight](https://wwwnc.cdc.gov/eid/spotlight/hiv) * [Influenza Spotlight](https://wwwnc.cdc.gov/eid/spotlight/influenza) * [Lyme Disease Spotlight](https://wwwnc.cdc.gov/eid/spotlight/lyme-disease) * [Malaria Spotlight](https://wwwnc.cdc.gov/eid/spotlight/malaria) * [MERS Spotlight](https://wwwnc.cdc.gov/eid/spotlight/mers) * [Mpox Spotlight](https://wwwnc.cdc.gov/eid/spotlight/mpox) * [Pneumonia Spotlight](https://wwwnc.cdc.gov/eid/spotlight/pneumonia) * [Rabies Spotlight](https://wwwnc.cdc.gov/eid/spotlight/rabies) * [Ticks Spotlight](https://wwwnc.cdc.gov/eid/spotlight/ticks) * [Tuberculosis/Mycobacteria](https://wwwnc.cdc.gov/eid/spotlight/tuberculosis) * [Zika Spotlight](https://wwwnc.cdc.gov/eid/spotlight/zika) * [ Home](https://wwwnc.cdc.gov/) * [Article Type Search](https://wwwnc.cdc.gov/eid/ArticleTypeSearch) * [EID on PubMed Central](https://www.ncbi.nlm.nih.gov/pmc/journals/782/) * [ Home](https://wwwnc.cdc.gov/) * [Subscribe](https://wwwnc.cdc.gov/eid/subscriptions) * [Author Resource Center](https://wwwnc.cdc.gov/eid/page/author-resource-center) * [Peer Reviewers](https://wwwnc.cdc.gov/eid/reviewers) * [Podcasts](https://wwwnc.cdc.gov/eid/podcasts) * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article) **Podcasts** * [Search](https://wwwnc.cdc.gov/eid/podcasts/search) * [ Home](https://wwwnc.cdc.gov/) * [Social Media](https://wwwnc.cdc.gov/eid/page/social-media) * [ Press & Media Information](https://wwwnc.cdc.gov/eid/press) * [ Home](https://wwwnc.cdc.gov/) 1. [EID Journal](https://wwwnc.cdc.gov/eid/) 2. [Volume 32](https://wwwnc.cdc.gov/eid/early-release) 3. [Early Release](https://wwwnc.cdc.gov/eid/early-release#issue-1349) 4. [Main Article](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article) * [Facebook](https://www.facebook.com/sharer/sharer.php?u=%2Feid%2Farticle%2F32%2F12%2F26-1060_article "Share to Facebook") * [Twitter](http://twitter.com/share?url=%2Feid%2Farticle%2F32%2F12%2F26-1060_article&text= "Share to Twitter") * [LinkedIn](https://www.linkedin.com/shareArticle?url=%2Feid%2Farticle%2F32%2F12%2F26-1060_article&title= "Share to LinkedIn") * [Syndicate](https://tools.cdc.gov/medialibrary/index.aspx#/sharecontent//eid/article/32/12/26-1060_article "Embed this Page") [ Emerging Infectious Disease journal ISSN: 1080-6059 ](https://wwwnc.cdc.gov/eid/) _Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released._ #### Volume 32, Supplement—December 2026 SUPPLEMENT ISSUE ##### _Supplement_ ### Transplant-Associated _Ehrlichia ewingii_ Infection in Pediatric Liver Recipient, United States, 2023 On This Page [The Study](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article) * * * [Conclusions](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article) * * * [Cite This Article](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article) Figures [Figure](https://wwwnc.cdc.gov/eid/article/32/14/26-1060-f1) Tables [Table](https://wwwnc.cdc.gov/eid/article/32/14/26-1060-t1) Downloads [RIS [TXT - 2 KB] ](https://wwwnc.cdc.gov/eid/article/32/14/26-1060.ris) Article Metrics [Metric Details](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article) Related Articles [_Borrelia duttonii_](https://wwwnc.cdc.gov/eid/article/32/14/26-0269_article) * * * [Rocky Mountain Spotted Fever, Arizona](https://wwwnc.cdc.gov/eid/article/32/14/26-1120_article) * * * [Fatal Disseminated Powassan Virus Infection in Transplant Recipient, Pennsylvania, USA](https://wwwnc.cdc.gov/eid/article/32/12/26-0193_article) * * * [More articles on Ticks](https://wwwnc.cdc.gov/eid/spotlight/ticks) Mohamad Shieb, Sushmitha Grama Srinivasan, Julie K. Heimbach, Samar H. Ibrahim, Elizabeth Schiffman, Alex Garvin, Jennifer Brown, Kira L. Richardson, David W. McCormick, Sandor E. Karpathy, Arlyn N. Gleaton, Carmen Ramos, Joseph Singleton, Pallavi Annambhotla, Sridhar V. Basavaraju, Jennifer Kasten, Christopher D. Paddock, Johanna S. Salzer, Bobbi Pritt, Brenda Schiltz, and Elizabeth H. Ristagno[![Comments to Author](https://wwwnc.cdc.gov/eid/content/images/icon/email.gif)](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article#comment) Author affiliation: Mayo Clinic, Rochester, Minnesota, USA (M. Shieb, J.K. Heimbach, S.H. Ibrahim, B. Pritt, B. Schiltz, E.H. Ristagno); Stanford University, Stanford, California, USA (S. Grama Srinivasan); Minnesota Department of Health, St. Paul, Minnesota, USA (E. Schiffman, A. Garvin); Indiana Department of Health, Indianapolis, Indiana, USA (J. Brown, K.L. Richardson); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (D.W. McCormick, S.E. Karpathy, A.N. Gleaton, C. Ramos, J. Singleton, P. Annambhotla, S.V. Basavaraju, J. Kasten, C.D. Paddock, J.S. Salzer) [Cite This Article](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article "Show Article Citations") Open modal [Citation for Media](https://wwwnc.cdc.gov/eid/press) ### Abstract We report a case investigation of a pediatric patient in the United States who experienced fever, nausea, dyspnea, and pancytopenia 18 days after a liver transplant. Diagnostic testing and public health investigation confirmed a donor-derived _Ehrlichia ewingii_ infection. This case highlights rare tickborne pathogens as a cause of donor-derived infections and the consideration for extended antimicrobial therapy. Ehrlichiosis is characterized by influenza-like symptoms such as fever, headache, nausea, and muscle aches. In the United States, ehrlichiosis can be caused by infections from 3 pathogenic tickborne bacterial species, _Ehrlichia chaffeensis_ , _Ehrlichia ewingii_ , and _Ehrlichia muris_ subsp. _eauclairensis_. The epidemiology of _E. chaffeensis_ and _E. ewingii_ is associated with the distribution of the lone star tick (_Amblyomma americanum_), which occurs primarily in the northeastern, southern, and midwestern United States. _E. muris_ subsp. _eauclairensis_ infections are isolated to Wisconsin and Minnesota and transmitted by the blacklegged tick (_Ixodes scapularis_) ([_1_](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article#r1 "1")). During 2008–2022, a total of 327 cases of _E. ewingii_ infection from 28 states were reported to the Centers for Disease Control and Prevention (CDC), compared with 19,918 cases of _E. chaffeensis_ infections from 47 states ([_2_](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article#r2 "2"),[_3_](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article#r3 "3")). _E. ewingii_ infections are likely underreported because diagnosis relies on serologic assays that cannot differentiate among _Ehrlichia_ species. The nonspecific clinical signs and symptoms of ehrlichiosis and gaps in healthcare provider knowledge contribute to underdiagnosis and underreporting ([_2_](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article#r2 "2")). Ehrlichiosis is uncommon among transplant recipients, and donor-derived infections are exceedingly rare ([_4_](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article#r4 "4")). Here, we report on a case of _E. ewingii_ infection in a pediatric liver recipient. ### The Study In the fall of 2023, a child 10–15 years of age with end-stage liver disease secondary to primary sclerosing cholangitis underwent deceased donor liver transplantation. The child had no travel outside the state in which the transplant was performed within the 10 weeks before the surgery and had no outdoor or animal exposures and no known tick bites. The child permanently resided outside the United States, in an area where ehrlichiosis has not been reported. Transplant surgery was uncomplicated and required only autologous cell saver transfusion. At transplantation, serologic testing revealed IgG to Epstein-Barr virus and cytomegalovirus in both the donor and recipient. The liver recipient received intravenous (IV) methylprednisolone (500 mg, followed by 50 mg every 12 h with taper), mycophenolate mofetil (883 mg IV every 12 h, transitioned to 1,000 mg oral every 12 h), and oral tacrolimus (3 mg every 12 h), as part of standard immunosuppressive therapy. Ten days after transplantation, a biopsy revealed mild acute cellular rejection in the patient. The patient was treated with IV methylprednisolone (1,000 mg every other day for 3 doses). Asymptomatic cytomegalovirus viremia developed in the patient 12 days after transplantation and resolved with oral valganciclovir (900 mg every 12 h). The patient reported fever, headache, dyspnea, and severe nausea 18 days after transplantation and was admitted to the hospital. Blood and urine cultures yielded no growth, and imaging revealed no abnormalities; laboratory testing showed anemia, leukopenia, and thrombocytopenia. During the next 72 hours, progressive tachypnea developed in the patient, oxygen saturation decreased, and fever persisted (maximum temperature 40.5°C). The patient was started on intravenous doxycycline (100 mg 2×/d) 24 days after transplantation for suspected atypical pneumonia and tickborne disease infection. Within 24 hours of treatment, the patient’s fever resolved, other symptoms improved, and laboratory abnormalities resolved. Figure ![Peripheral blood smear from a pediatric liver recipient with laboratory-confirmed Ehrlichia ewingii infection, United States, 2023. Wright-Giemsa staining shows morulae \(arrows\) within granulocytes. Original magnification ×1,000. ](https://wwwnc.cdc.gov/eid/images/26-1060-F1-tn.jpg) [Figure](https://wwwnc.cdc.gov/eid/article/32/14/26-1060-f1 "Figure"). Peripheral blood smear from a pediatric liver recipient with laboratory-confirmed _Ehrlichia ewingii_ infection, United States, 2023. Wright-Giemsa staining shows morulae (arrows) within granulocytes. Original magnification ×1,000. At initiation of doxycycline treatment, examination of a peripheral smear revealed findings in granulocytes suggestive of _Anaplasma_ or _Ehrlichia_ species bacteria ([Figure](https://wwwnc.cdc.gov/eid/article/32/14/26-1060-f1)). Mayo Clinic (Rochester, MN, USA) performed real-time PCR for _E. ewingii_ and _Ehrlichia canis_ on a whole-blood sample collected 24 days after transplantation; results were positive ([_5_](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article#r5 "5")). CDC (Atlanta, GA, USA) performed confirmatory testing by using real-time PCRs targeting segments of the 16S rRNA gene. Testing detected _Ehrlichia_ spp. DNA but not _E. chaffeensis_ DNA _._ Subsequent partial 16S rRNA sequencing confirmed the presence of _E. ewingii_ DNA. The patient continued doxycycline treatment, and clinicians changed _Pneumocystis jirovecii_ prophylaxis from oral trimethoprim/sulfamethoxazole (160/800 mg 3×/wk) to inhaled pentamidine (300 mg) because of a potential contraindication to trimethoprim/sulfamethoxazole in rickettsial infections ([_6_](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article#r6 "6")). Because ehrlichiosis is nationally notifiable in the United States, clinicians reported the case to public health officials. The Department of Health in the state where the transplant surgery occurred initiated an epidemiologic investigation, in collaboration with CDC and the Department of Health in the state where the deceased donor resided. The deceased donor resided in an area where _E. ewingii_ has been identified in _A. americanum_ ticks and human cases have been reported ([_2_](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article#r2 "2")). Thirty days before organ donation, the donor sought medical care for a mild, self-limiting illness compatible with ehrlichiosis, including headache, abdominal pain, nausea, and chills. The donor subsequently died of a confirmed noninfectious cause. CDC retrospectively tested serum collected from the donor at organ procurement by using an indirect immunofluorescence antibody assay, which detected IgG reactive with _E. chaffeensis_ at a titer of 1:2,048. CDC testing did not detect _Ehrlichia_ spp. DNA by using real-time PCR in donor serum or in a whole-blood sample collected from the recipient on the day of transplantation ([_7_](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article#r7 "7")). CDC tested liver allograft biopsy specimens obtained before and after transplantation and did not detect _Ehrlichia_ spp _._ antigens by using immunohistochemistry or _Ehrlichia_ spp. DNA by using real-time PCR ([_8_](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article#r8 "8")). The clinical history and geographic location of the donor, along with laboratory evidence, strongly supports a donor-derived _E._ _ewingii_ infection. Surgeons also transplanted both donor kidneys. Investigators notified the treating clinicians for both kidney recipients of possible transplant-associated infection. Neither kidney recipient reported signs or symptoms associated with ehrlichiosis. PCR testing of whole-blood samples from the recipients did not detect _Ehrlichia_ spp _._ DNA, and serologic testing was not performed. The liver recipient was discharged on day 28 after transplantation with oral doxycycline (100 mg 2×/d). Mayo Clinic performed additional real-time PCR testing ([_5_](https://wwwnc.cdc.gov/eid/article/32/14/26-1060_article#r5 "5")) for _E. ewingii_ and _E._ _canis_ on whole-blood samples collected from the liver recipient on days 35, 42, 49, and 56 after transplantation (days 11, 19, 25, and 32 of doxycycline treatment); all samples yielded positive results ([Table](https://wwwnc.cdc.gov/eid/article/32/14/26-1060-t1)). On day 67 after transplantation (day 43 of doxycycline treatment), real-time PCR testing for _E. ewingii_ and _E._ _canis_ on a whole-blood sample from the liver recipient yielded negative results ([Table](https://wwwnc.cdc.gov/eid/article/32/14/26-1060-t1)). Subsequent real-time PCR testing on day 68 after transplantation yielded negative results, and clinicians discontinued doxycycline treatment. However, on day 98 after transplantation, real-time PCR testing of a whole-blood sample yielded positive results. At that time, the patient had a cough, and chest radiography revealed peribronchial thickening not attributable to ehrlichiosis. Clinicians subsequently treated the patient with albuterol and systemic steroids and reinitiated doxycycline treatment. Real-time PCR testing for _E. ewingii_ and _E._ _canis_ PCR revealed alternating negative and positive results in the subsequent days, suggesting low-level bacteremia ([Table](https://wwwnc.cdc.gov/eid/article/32/14/26-1060-t1)). Of note, the patient remained asymptomatic, and serologic testing did not detect antibodies reactive to _E. chaffeensis_ throughout the follow-up period. The patient remained on doxycycline for an extended period of >273 days after transplantation. The patient did not return for the requested infecti
## Related Clinical Research

- [Influenza and Coronavirus: Comparative Evolution, Epidemiology, Antivirals, and Vaccines](https://medichelpline.com/clinical-feed/pubmed-43058094.md) (DOI: 10.1038/s41392-026-03078-5)
- [Sex differences in antibody breadth and memory after seasonal H3N2 influenza vaccination](https://medichelpline.com/clinical-feed/medrxiv-14-broader-functional-and-memory-antibody-responses-in-adult-females-than-males-in.md)
- [Borrelia duttonii: agent of African tick‑borne relapsing fever](https://medichelpline.com/clinical-feed/cdc-emerging-infectious-diseases-journal-0-borrelia-duttonii.md)
- [US Influenza Activity 2025–26: Early A(H3N2) Peak, Two Waves, and Pediatric Burden](https://medichelpline.com/clinical-feed/medrxiv-4-influenza-activity-in-the-united-states-during-the-2025-26-influenza-season.md)
- [Canine TMPRSS4 in MDCK sublines enables trypsin-independent influenza A virus replication](https://medichelpline.com/clinical-feed/biorxiv-2-endogenous-serine-proteases-in-mdck-sublines-support-trypsin-independent.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.